🇨🇳🇭🇰 That Was The Week That Was • Hong Kong/China - 12th~18th August 2019 @Smartkarma
• TW3 HONG KONG/CHINA 12~18 AUGUST •The weight of this week's 28 China/Hong Kong Insights was surprisingly more bullish in its tone (18 bull/10...
373 Views
CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
496 Views
CStone Pharma's (基石药业) Lock-Up Expiry - Lack of Material Newsflow for Core Drug Candidates
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
513 Views
HK IPO Analytics 1H2019: MS and CICC Stand Out
At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
616 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
586 Views